Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Advances in Cancer Research
|
June 30, 2001
Recombinant immunotoxins in targeted cancer cell therapy
Y Reiter
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1996
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins
Y Reiter, I Pastan
Journal of Immunology (Baltimore, Md. : 1950)
|
April 15, 1989
Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b
Y Reiter, Z Fishelson
Molecular Immunology
|
June 1, 1992
Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP)
Y Reiter, Z Fishelson
Trends in Biotechnology
|
January 9, 1999
Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis
Y Reiter, I Pastan
Targeted Diagnosis and Therapy
|
January 1, 1989
Killing of human tumor cells by antibody C3b conjugates and human complement
Y Reiter, Z Fishelson
European Journal of Immunology
|
May 1, 1992
Sublytic complement attack protects tumor cells from lytic doses of antibody and complement
Y Reiter, A Ciobotariu, Z Fishelson
Oncogene
|
May 29, 2007
Novel antibodies as anticancer agents
I Zafir-Lavie, Y Michaeli, Y Reiter
Journal of Immunology (Baltimore, Md. : 1950)
|
June 22, 2001
Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR
G Denkberg, C J Cohen, Y Reiter
Nature Biotechnology
|
October 1, 1996
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
Y Reiter, U Brinkmann, B Lee, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Advances in Cancer Research
|
June 30, 2001
Recombinant immunotoxins in targeted cancer cell therapy
Y Reiter
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1996
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins
Y Reiter, I Pastan
Journal of Immunology (Baltimore, Md. : 1950)
|
April 15, 1989
Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b
Y Reiter, Z Fishelson
Molecular Immunology
|
June 1, 1992
Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP)
Y Reiter, Z Fishelson
Trends in Biotechnology
|
January 9, 1999
Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis
Y Reiter, I Pastan
Targeted Diagnosis and Therapy
|
January 1, 1989
Killing of human tumor cells by antibody C3b conjugates and human complement
Y Reiter, Z Fishelson
European Journal of Immunology
|
May 1, 1992
Sublytic complement attack protects tumor cells from lytic doses of antibody and complement
Y Reiter, A Ciobotariu, Z Fishelson
Oncogene
|
May 29, 2007
Novel antibodies as anticancer agents
I Zafir-Lavie, Y Michaeli, Y Reiter
Journal of Immunology (Baltimore, Md. : 1950)
|
June 22, 2001
Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR
G Denkberg, C J Cohen, Y Reiter
Nature Biotechnology
|
October 1, 1996
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
Y Reiter, U Brinkmann, B Lee, et al.
Page
of 4